First-ever gene therapy for hearing loss gets FDA approval: 'Groundbreaking'

The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...
EurekAlert!

BU researchers discovering new mosquito-specific viruses

Aedes aegypti, commonly known as the yellow fever mosquito, is a highly adapted, invasive mosquito species recognized as a major global health threat that acts as the primary vector for several severe ...
Electronics360

Rohde & Schwarz joins FormFactor’s MeasureOne partner program

FormFactor, Inc, a provider of radio frequency (RF) probe stations and probe cards, and Rohde & Schwarz, a global leader in ...

Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program

Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ...

Zilliz is recognized as a 'Stars Company' in MarketsandMarkets' latest 360Quadrant for the Vector Database Market

Zilliz, the creator of Milvus -- the world's most widely adopted open-source vector database with over 43,000 GitHub stars and more than 10,000 enterprise deployments -- has been recognized as a ...